

17th Symposium on Pharmacokinetics and Drug Metabolism, 12-13 november 2024

Agenda at glance

Tuesday 12 th November		Wednesday 13 th November	
11.30 – 13.00	Registration and Lunch	08.30 – 10.15	Session 3: Pharmacokinetic and pharmacodynamic considerations in rare disease and special populations
13.00 – 13.15	Opening and introduction of meeting	10.15 – 10.45	Break with posters & coffee
13.15 – 14.45	Session 1: Biotransformation and impact of drug metabolites	10.45 – 12.15	Session 4: Bridging strategies for drug-device products
14.45 – 15.30	Break with posters & coffee	12.15 – 13.15	Lunch
15.30 – 17.00	Session 2: Drug Transporter considerations across drug modalities	13.15 – 13.45	Rosenön Award
17.00 – 17.15	Break	13.45 – 14.45	Session 5: Pharmacokinetics-Pharmacodynamics of drug combination therapies
17.15 – 18.00	Candlelight lecture	14.45 – 15.00	Closure of meeting
18.00 – 18.45	Break & refreshments and poster session		
19.00 – 23.00	Dinner		

Confirmed speakers with preliminary titles

Tuesday, 12th November

Session 1: Biotransformation and impact of drug metabolites

13:15 - 14:45

Chairs: Johanna Haglund, MetaSafe, Johan Bylund, CTC, Clinical Trial Consultants

Speakers:

- "Unusual" Biotransformation Reactions of Drugs and Drug Candidates, Emre Isin, Servier
- Drug metabolism in drug discovery-PK, PD and safety aspects, Carl Petterson, Merck Healthcare
- Structural elucidation of conjugation drug metabolites by utilizing novel electron-activated dissociation (EAD), Ferran Sánchez, SCIEX

Session 2: Drug transporter considerations across drug modalities

15:30 - 17:00

Chairs: Anna Nordmark, Nordmark ClinPharm consulting, Rasmus Jansson-Löfmark, AstraZeneca

Speakers:

- Drug transporters and large molecules, Pär Matsson, Gothenburg University
- Antibody brain exposure and distribution using a passive or an active transport mechanism in the mission to target brain diseases, Sofia Gustafsson, BioArctic
- Translational aspects of oxycodone brain delivery via the proton-coupled organic cation (H⁺/OC) antiporter system: the journey from cells to pigs. Irena Loryan, Translational Pharmacokinetics/Pharmacodynamics group, Dep of Pharmacy Uppsala University
- Use of endogenous biomarkers for transporter DDI risk assessments and delineation of complex DDI mechanisms – Case studies from AstraZeneca, Vijender Panduga, AstraZeneca

Candlelight speaker:

17:15 – 18:00

Scope: The Candlelight Keynote lecture is a recurring feature from the Swedish Pharmaceutical Society and started as a serendipity. A number of symposiums back (called Rosenön meeting) there was a big snowstorm and the power was shut down. To continue with the show, the conference moved to the cafeteria where candles were lit and the lecture was continued. Ever since, there has been a so-called Candlelight Lecture where an important contributor to the field of PK and Drug Metabolism has been invited to present their career highlights in “unplugged version”. However now, sit back and enjoy this year’s speaker.

Speaker: Bengt Dahlström, PhD, Associate Professor

Bengt Dahlström is Associate Professor in Pharmacokinetics and Drug Therapy from Uppsala University, Sweden and has published over 50 scientific papers in this area. He is an expert in pharmacokinetics, drug research and development with over 40 years’ experience from leading positions in Pharmaceutical companies and CROs. He is co-founder of leading Clinical Research Organizations: CTC AB, PMC AB, MiniDoc AB and AB Biopharmacon.

Wednesday, 13th of November

Session 3: Pharmacokinetic and pharmacodynamic considerations in rare disease and special populations

08:30 – 10:15

Chairs: Anna Nordmark, Nordmark ClinPharm Consulting, Mia Lundblad, Novo Nordisk, Pawel Baranczewski SciLifeLab, Uppsala University

Speakers:

- **Physiologically based pharmacokinetic modelling and simulation in perinatal populations: opportunities, challenges and case examples**, Pieter Annaert, Drug Delivery and Disposition, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium
- **PBPK simulations in special populations. Are we ready for prime time?** Eva Berglund, Certara Drug Development Services, Certara
- **Clinical Pharmacology considerations for development of Sogroya (somapacitan) for rare pediatric growth disorders**, Rasmus Juul Kildemoes, Clinical Pharmacology RD&AT, Novo Nordisk
- **Model-informed development of Mim8 - a novel bispecific antibody for the treatment of haemophilia A**, Mads Kreilgaard, Pharmacometrics, Novo Nordisk

Session 4: Bridging strategies for drug-device products

10:45 - 12:15

Chairs: Markus Fridén, AstraZeneca, Mia Lundblad, Novo Nordisk

Speakers:

- **Ambition Zero Carbon: Accelerating adoption of Next Generation Propellant inhalation sprays by linking propellant and aerosol physics to predicted lung efficacy**, Duy Nguyen & Michael Williams, AstraZeneca
- **Preliminary title: Improved bioequivalence assessment through model-informed and model-based strategies**, Andy Hooker, Uppsala University
- **Biopharmaceutical Evaluation of the Subcutaneous Administration**, Marta Vencel, Sanofi

Session 5: Pharmacokinetics-Pharmacodynamics of drug combination therapies

13:45 – 14:45

Chairs: Markus Fridén, AstraZeneca, Rasmus Jansson-Löfmark, AstraZeneca

Speakers:

- **Development of a pre-clinical model-based drug regimen platform for antibiotics within a European perspective**, Ulrika Simonsson, Uppsala University
- **Speaker – to be confirmed**